Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07712692 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of NWRD09 for HPV-16 Related Cervical HSIL

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD09 administered by intramuscular (IM) injection in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16.
Trial Details
NCT Number NCT07712692
Lead Sponsor Newish Biotech (Wuxi) Co., Ltd.
Conditions
(from sponsor)		 High-grade Squamous Intraepithelial Lesion (HSIL)
Related terms Squamous Intraepithelial Lesions
Enrollment 156 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov